Greenphire and Oracle to Work Together
News Jun 25, 2013
Greenphire has announced a relationship with Oracle Health Sciences. Oracle and Greenphire are integrating their respective product suites to enable their clients to streamline and automate processes from trial planning and budgeting, all the way through data capture to executing payments to clinical sites and patients, while providing real-time, strategically valuable reporting and analytics.
The first initiative will be the integration of Greenphire’s global payment platform, eClinicalGPS, with Oracle’s electronic data capture (EDC) solutions, Oracle Health Sciences InForm and Oracle Remote Data Capture (RDC).
This integration will help ensure that clients have quick product implementations without relying on internal development and staffing.
Data sharing between EDC and payment technologies will enable a virtually seamless transition between the collection and capture of clinical data and the accurate execution of payments.
Greenphire and Oracle are currently working with three joint clients including two top 10 global biopharmaceutical clients and a fast growing biotechnology client.
“Clinical trial sponsors and their CRO partners are focused on improving productivity and efficiency across their clinical programs - including study set up, recruitment, data collection and analysis, as well as the administration of and payments to research sites and participants. Integrations between the Oracle and Greenphire product suites can help biopharmaceutical companies and CROs achieve new levels of efficiency and deliver powerful analytics that support continuous improvement. This will enable companies to re-direct freed up resources to discovery and development initiatives,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences.
“Greenphire is committed to continually finding ways to increase efficiencies in clinical research processes and to drive value and cost savings for our clients,” said Greenphire Founder & CEO Sam Whitaker.
Whitaker continued, “Our relationship with Oracle is a tremendous opportunity to find innovative ways to streamline existing processes and to ultimately simplify financial planning and management of clinical trials, by working with a company that offers world-class e-clinical solutions.”
Biomedical Catalyst Award Goes To BioMoti, Pharmidex and Queen Mary University of LondonNews
The grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard-to-treat tumours including advanced ovarian, triple negative breast and pancreatic cancers.READ MORE
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE